These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 24718982)

  • 1. An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors.
    Maison-Blanche P; Dakhil S; Baron A; Rottey S; Millard F; Daugaard G; Machiels JP; Conkright W; Sharma S; Soetekouw PM; Yachnin J; Sengeløv L; Van Veldhuizen P; Agarwala SS; Sémiond D; Chadjaa M; Shen L; Wade JL
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1241-52. PubMed ID: 24718982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
    He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
    Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.
    Chen N; Chawla SP; Chiorean EG; Read WL; Gorbaty M; Mita AC; Yung L; Bryan P; McNally R; Renschler MF; Sharma S
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):1083-94. PubMed ID: 23400695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
    Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.
    Maison-Blanche P; Vermorken JB; Goksel T; Machiels JP; Agarwala S; Rottey S; Daugaard G; Volovat C; Scheulen M; Sengeløv L; Grecea D; Eniu A; Jäger E; Meiri E; Cascinu S; Strumberg D; Demir G; Clemens M; Pinotti G; Nardi M; Guthrie T; Boelle E; Magherini E
    J Cardiovasc Pharmacol; 2013 Jun; 61(6):495-504. PubMed ID: 23429593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.
    Molife LR; Rudman SM; Alam S; Tan DS; Kristeleit H; Middleton G; Propper D; Bent L; Stopfer P; Uttenreuther-Fischer M; Wallenstein G; de Bono J; Spicer J
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1213-22. PubMed ID: 24085260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
    Wang Z; Grasela DM; Krishna G
    Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study.
    Xu N; Redfern CH; Gordon M; Eppler S; Lum BL; Trudeau C
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1251-60. PubMed ID: 25344761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma.
    Burke JM; van der Jagt RH; Flinn IW; Craig MD; Chen L; Morganroth J; Munteanu MC; MacDonald DA
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):211-6. PubMed ID: 26006703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study.
    Munasinghe W; Stodtmann S; Tolcher A; Calvo E; Gordon M; Jalving M; de Vos-Geelen J; Medina D; Bergau D; Nuthalapati S; Hoffman D; Shepherd S; Xiong H
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1003-1011. PubMed ID: 27709282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac repolarization with Gabapentin enacarbil in a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults.
    Davy M; Upward J; Arumugham T; Twomey C; Chen C; Stier B
    Clin Ther; 2013 Dec; 35(12):1964-74. PubMed ID: 24290737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.
    Munasinghe WP; Mittapalli RK; Li H; Hoffman DM; Holen KD; Menon RM; Xiong H
    Cancer Chemother Pharmacol; 2017 May; 79(5):915-922. PubMed ID: 28349167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.
    Jones RL; Bendell JC; Smith DC; Diefenbach K; Lettieri J; Boix O; Lockhart AC; O'Bryant C; Moore KN
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):777-84. PubMed ID: 26281907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study.
    Diéras V; Lortholary A; Laurence V; Delva R; Girre V; Livartowski A; Assadourian S; Semiond D; Pierga JY
    Eur J Cancer; 2013 Jan; 49(1):25-34. PubMed ID: 22975213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors.
    Deeken JF; Shimkus B; Liem A; Hill D; Gurtler J; Berghorn E; Townes L; Lu H; Trifan O; Zhang S
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1473-83. PubMed ID: 23589315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
    Olszanski AJ; Smith DC; Camacho LH; Thompson J; Ramalingam SS; Harvey RD; Campos L; Ferry D; Tang S; Gao L; Safran H
    Oncologist; 2016 Apr; 21(4):402-3. PubMed ID: 26984445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors.
    Hoffman J; Chakrabarti J; Plotka A; Milillo Naraine A; Kanamori D; Moroose R; Nguyen L; Wang D; Wainberg ZA
    Anticancer Drugs; 2019 Jun; 30(5):523-532. PubMed ID: 30875341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies.
    Morcos PN; Bogman K; Hubeaux S; Sturm-Pellanda C; Ruf T; Bordogna W; Golding S; Zeaiter A; Abt M; Balas B
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):559-568. PubMed ID: 28243683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.